Chemours stock
CCNYSEThe Chemours Company, Basic MaterialsISIN US1638511089
32Score 32 out of 100, Weak
Price and trend
42 / 100
Price history
+5.9% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 27% below it.
Since August 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 56).
The price is 52% below its 52-week high. Largest decline in 11 years: 87% (October 2017 to April 2020).
Chart figures for advanced users
- SMA 50$13.80
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$18.29
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)56
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$10.48
- The lowest closing price of the last twelve months.
- Resistance$27.94
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- The Chemours Company belongs to the Chemicals (Specialty) industry (United States) and, with a market value of $2.01B, is number 82 of 108 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $5.81B (up 0.4% year on year) and a loss of $386M.
- For fiscal 2026, analysts expect on average revenue of $5.93B (up 2.1%) and adjusted earnings per share of $0.83 (down 13.9%).
Show more
- MEQIRI Score 32 out of 100 (Weak): rank 432 of 467 in Basic Materials, median 58.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 61.2% a year through 2027 (estimates from 5 analysts).
- Share buybacksShare count down 9% since 2020.Capital allocation 50
Weaknesses
- High debtDebt 25.8 times equity (latest quarter), Chemicals (Specialty) median 0.63.Stability 26
- Margin fallingOperating margin −0.1%, average of the prior years 9% (to 2024).Profitability 13
- Loss-makingLoss of $168M over the last 12 months.Fundamentals 48
The score is held back by profitability and valuation.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
- high price swings
- cyclical sector (energy or materials), as a group, crashed more often in the backtest
What lowers it
- low growth grade (crashed less often in the backtest)
Valuation
Valuation signal
OvervaluedClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 0.5% on the twelve months before. Revenue has stayed largely stable since 2011.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 16%, operating 0%, net −7%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 18 Feb 2027in 98 days
- Last reported
- 2 Nov 2026EPS reported $0.21 (expected $0.27)below expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 13.9% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.83−13.9%
- Revenue
- $5.93B+0.2%
- Earnings per share
- $1.75−8.2%
- Revenue
- $6.14B−1.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −15.7%Third quarter and full-year outlook updated, but the company did not state the direction versus before; capex of $250 million to $280 million expected.
“Capital expenditures are expected to be between $250 million and $280 million for the full year, with free cash flow conversion above 25%, reflecting higher earnings and improvements in working capital throughout the year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
7 insiders bought on the open market between 6 Aug 2026 and 12 Aug 2026, $488,619 in total.
- Familiar Calderon GerardoPurchase
12 Aug 2026, See Remarks
- Shares
- 1,935
- Price
- $15.53
- Value
- $30,051
- Dignam DenisePurchase
11 Aug 2026, Chief Executive Officer
- Shares
- 3,378
- Price
- $14.95
- Value
- $50,501
- Cowan AlisterPurchase
7 Aug 2026, Board
- Shares
- 13,000
- Price
- $15.62
- Value
- $203,060
Show 4 more
- Foley Michael RobertPurchase
7 Aug 2026, See Remarks
- Shares
- 1,934.23
- Price
- $15.51
- Value
- $30,000
- Cranston Mary BPurchase
7 Aug 2026, Board
- Shares
- 6,000
- Price
- $15.83
- Value
- $94,950
- Martinko Joseph T.Purchase
7 Aug 2026, See Remarks
- Shares
- 1,939.8
- Price
- $15.47
- Value
- $30,009
- Hostetter ShanePurchase
6 Aug 2026, Chief Financial Officer
- Shares
- 3,350
- Price
- $14.94
- Value
- $50,049
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Chemours
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
467 rated companies in Basic Materials
- This company
- 32
- Sector median
- 58
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Chemicals (Specialty)
The next larger and next smaller companies by market value
- WD-40WDFC $2.94B73
- H.B. FullerFUL $2.73B53
- Quaker HoughtonKWR $2.68B54
- IngevityNGVT $2.14B60
- Minerals TechnologiesMTX $1.93B45
- InnospecIOSP $1.93B64
- VERBIO Vereinigte BioEnergieVBK.DE $1.86B53
- CorbionCRBN.AS $1.71B66
ETFs that hold Chemours
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Hydrogen Economy UCITS ETF USDHTMW | 2.40% | 0.49% | €394.28M |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.11% | 0.30% | €2.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.07% | 0.30% | €185.82M |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.07% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.07% | 0.30% | €2.17B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.05% | 0.30% | €944.34M |
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.04% | 0.39% | €1.47B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.03% | 0.43% | €2.48B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 20 Feb 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.